Brand-name drug
Spravato price, strengths & recalls
Brand of esketamine (generic)
Pharmacies pay $1,288.12 for 3 vials of Spravato 84 mg dose kit pack this week, and from $854.37 to $1,288.12 across its 2 priced strengths and forms. Its official label last changed on September 24, 2026.
Brand- Fair cash price
- $1,491.84
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Spravato price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 56 mg dose kit pack Brand | $427.19 | $854.37 / 2 vials |
| 84 mg dose kit pack Brand | $429.37 | $1,288.12 / 3 vials |
Spravato vs generic esketamine
There is no generic version of Spravato on the market yet. Its last listed patent or exclusivity runs to February 18, 2040 - generics often follow, though court cases and settlements can move the date either way.
GenericEsketamine pricesSupply status: shortages & recalls
What people paid for Spravato
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SPRAVATO safely and effectively. See full prescribing information for SPRAVATO. SPRAVATO® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)
WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS
WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration. (
5.1,
5.2,
5.3)
Potential for abuse and misuse. Consider the risks and benefits of prescribing SPRAVATO prior to using in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse. (
5.4)
SPRAVATO is only available through a restricted program called the SPRAVATO REMS. (
5.5)
Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. SPRAVATO is not approved for use in pediatric patients. (
5.6)
Sedation
Patients are at risk for sedation after administration of SPRAVATO
[see
Warnings and Precautions (5.1)].
Dissociation
Patients are at risk for dissociative or perceptual changes after administration of SPRAVATO
[see
Warnings and Precautions (5.2)].
Respiratory Depression
Respiratory depression has been observed in postmarketing experience
[see
Warnings and Precautions (5.3)].
Because of the risks of sedation, dissociation, and respiratory depression, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting
[see
Warnings and Precautions (5.1,
5.2,
5.3)].
Abuse and Misuse
SPRAVATO has the potential to be abused and misused. Consider the risks and benefits of prescribing SPRAVATO prior to use in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse
[see
Warnings and Precautions (5.4)].
Because of the risks of serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse and misuse, SPRAVATO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS
[see
Warnings and Precautions (5.5)].
Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. SPRAVATO is not approved for use in pediatric patients
[see
Warnings and Precautions (5.6)].
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA211243 · Janssen Pharms
- First approved
- March 5, 2019 (7 years ago)
- Latest approved change
- September 17, 2026
- Approved label
- PDF, Oct 21, 2026
- Generic makers
- None on the market
- Last patent listed
- February 18, 2040
- Exclusivity ends
- January 17, 2028
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Spravato questions
How much does spravato cost without insurance?
Pharmacies pay about $1,288.12 for 3 vials of spravato 84 mg dose kit pack ($429.37 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,491.84. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Spravato?
Yes: esketamine. Compare esketamine prices.
Is spravato in shortage?
No shortage is reported for spravato right now. We check the national shortage list every day.
Has spravato been recalled?
No recalls are on record for spravato.
When did the spravato label last change?
The official label was last updated on September 24, 2026 (version 21). See what changed.
Talk about spravato
No comments yet. Questions, tips, what worked for you - start the conversation.